Results 161 to 170 of about 355,709 (346)

Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know? [PDF]

, 2001
Amit Bahl, Stephen Falk
openalex   +1 more source

Metabolism‐Regulating Nanomedicines for Cancer Therapy

Advanced NanoBiomed Research, EarlyView.
This review highlights metabolism‐regulating nanomedicines designed to target glycolytic, lipid, amino acid, and nucleotide pathways in tumors. By incorporating metabolism‐regulating agents into versatile nanocarriers such as liposomes, micelles, dendrimers, and engineered bacteria, these platforms achieve targeted delivery, controlled release ...
Xiao Wu, Shiyi Geng, Jian Yang
wiley   +1 more source

2036 A prospective randomized study of postoperative adjuvant chemo-radiotherapy (CT+RT) vs. radiotherapy (RT) alone in resected stage II and IIIA non-small cell lung cancer(NSCLC)

, 1995
Chang Geol Lee, Joo Hang Kim, Kyung YoungChung, Deuk Yong Lee, Kil Dong Kim, Won‐Young Lee, Sung Kyu Kim, Sei Kyu Kim, Gwi Eon Kim   +8 more
openalex   +1 more source

Interim analysis of a phase I/II dose escalation trial in non-small cell lung cancer (NSCLC) using three-dimensional conformal radiotherapy (3D-CRT) [PDF]

, 2001
J. Belderbos, Katrien De Jaeger, Wilma D. Heemsbergen, Paul Baas, Liesbeth Boersma, Joos V. Lebesque   +5 more
openalex   +1 more source

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

The Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari, Alberto Pavan, Alessandro Dal Maso, Valentina Da Ros, Giada Targato, Sabrina Vari, Stefano Indraccolo, Fiorella Calabrese, Stefano Frega, Laura Bonanno, Pier Franco Conte, Valentina Guarneri, Giulia Pasello   +21 more
wiley   +1 more source

2139 Chemotherapy followed by a combination of daily irradiation and carboplatine (CBDCA) in stage IIIB non small cell lung cancer (NSCLC): First interim analysis of a phase II trial

, 1996
É. Bardet, Jean‐Yves Douillard, A. Riviére, E. Quoix, D. Spaëth, A Ducoloné, Bruno Coudert, J.L. Lagrange, P Chomy, C. Tuchais, B. Pellae-Cosset, M. Henry‐Amar   +11 more
openalex   +1 more source

Up-regulation of a novel mRNA (NY-CO-1) involved in the methyl 4-methoxy-3-(3-methyl-2-butenoyl) benzoate (VT1)-induced proliferation arrest of a non-small-cell lung carcinoma cell line (NSCLC-N6) [PDF]

, 2001
Delphine Carbonnelle, Catherine Jacquot, X. Lanco, Gaëlle Le Dez, Christophe Tomasoni, G. Briand, Andrew Tsotinis, Theodora Calogeropoulou, Christos Roussakis   +8 more
openalex   +1 more source

Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non‐Small Cell Lung Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background LIBRETTO‐001 is an ongoing, global, open‐label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient‐reported outcomes in patients with RET fusion–positive non‐small cell lung cancer (NSCLC).
Anna Minchom, Aaron C. Tan, Erminia Massarelli, Vivek Subbiah, Valentina Boni, Bruce Robinson, Lori J. Wirth, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Caroline E. McCoach   +11 more
wiley   +1 more source

2201 Computed tomography (CT) and pulmonary function testing (PFT) correlation to morbidity following intra-operative I-125 brachytherapy for high risk non-small cell lung cancer (NSCLC)

, 1999
A.S. Chen, Michael Galloway, Rodney Landreneau, Shalom Kalnicki   +3 more
openalex   +1 more source

Lactylation in cancer biology: Unlocking new avenues for research and therapy

Cancer Communications, EarlyView.
Abstract Lactylation, a newly identified post‐translational modification, plays a multifaceted role in cancer biology by integrating epigenetic and non‐epigenetic mechanisms. This review summarizes the latest research progress on lactylation, including its functions in epigenetic regulation and its broader impact on cellular processes.
Xiaoyu Hou, Zhenya Hong, Huimin Zeng, Changyi Zhang, Peng Zhang, Ding Ma, Zhiqiang Han   +6 more
wiley   +1 more source